Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) was upgraded by stock analysts at William Blair to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.
Separately, UBS Group assumed coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research report on Friday, November 15th. They set a “buy” rating and a $21.00 price target for the company.
Read Our Latest Stock Report on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Stock Performance
See Also
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- What is Short Interest? How to Use It
- Tesla Investors Continue to Profit From the Trump Trade
- ESG Stocks, What Investors Should Know
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- How to Calculate Options Profits
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
